Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
AZN
Astrazeneca
$77.94
Chart
$69.26 (+12.53%)
$69.69 (+11.84%)
$74.93 (+4.02%)
$87.21 (-10.63%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
AZN
Astrazeneca
Current Price
$77.94
Login to view Astrazeneca (AZN) recommendation from the last 90 days from financial news and social media.
Chart
$69.26 (+12.53%)
$69.69 (+11.84%)
$74.93 (+4.02%)
$87.21 (-10.63%)
AZN Latest Analysis
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight. Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 |. DelveInsight The outlook for the gastric cancer treatment market appears favorable fueled by progress in targeted therapies and immunotherapies. Traditionally platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer underscoring the demand for more effective alte
Mon Aug 11, 2025
LNTH: Competition Escalates in PSMA Imaging. By Lantheus Holdings Inc. (NASDAQ:LNTH) reported second quarter 2025 financial and operational results on August 6th producing sales of $378 million a 4% decrease compared to 2Q:24 levels. Pylarify and TechneLite saw a year over year decline which was partially offset by an increase in revenue from Other Precision Diagnostics Strategic Partnerships and Definity sales. Free cash flow generation was $79 million in 2Q:25. however the cash balance decreas
Thu Aug 7, 2025
Alexion AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG). The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to UltomirisUltomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive (Ab) neuromyelitis opt
Thu Aug 7, 2025
HUTCHMED Reports 2025 Interim Results. — Indications expansion driving growth and ATTC platform enriching pipeline —— $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — the Company or we) (Nasdaq/AIM:HCM. HKEX:13) today reports its financial results for the six months ended June 30 2025 and provides updates on key clinical and commercial developments.HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English on Thu
Thu Aug 7, 2025
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 | DelveInsight. Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 |. DelveInsightThe market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth fueled by several major drivers. The rising incidence of chronic obstructive pulmonary disease primarily due to aging populat
Tue Aug 5, 2025
Sophia Genetics Expands Partnership With AstraZeneca . (RTTNews) - Sophia Genetics (SOPH) Tuesday announced an expansion of its partnership with AstraZeneca (AZN).
Tue Aug 5, 2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes. BOSTON and ROLLE Switzerland Aug. 5 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) a cloud-native healthcare technology company and a global leader in data-driven medicine today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new...
Tue Aug 5, 2025
Healthy Returns: AstraZeneca CEO proposes some United States drug price cuts amid Trump pressure. AstraZenecas CEO said the company has proposed United States price cuts to some drugs while Doximity enters competitive AI scribing market with new free offering.
Wed Jul 30, 2025
AstraZeneca Just Missed Estimates but Heres Why s Arent Worried Yet.
Wed Jul 30, 2025
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues Reaffirms 2025 Outlook. ) on Tuesday reported second-quarter 2025 sales of $14.46 billion up 12% year over year (11% at constant currency) marginally beating the driven by double-digit growth in oncology and biopharmaceuticals.The company'.s adjusted EPADSreached$1.08 missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).AstraZeneca'.s top business oncology (cancer) accounted for 44% of tot
Tue Jul 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings